Dysbiosis of the Gut Microbiota

Dysbiosis is a disrupted balance in the gut microbiota characterized by decreased microbial diversity and overgrowth of certain species. In healthy conditions, beneficial microbes maintain digestive health while keeping opportunistic pathogens in check. Dysbiosis breaks this equilibrium, reducing protective metabolites and increasing pro-inflammatory signaling that damages intestinal health.

Broad-spectrum antibiotics eliminate helpful commensal bacteria, enabling opportunistic pathogens like Clostridioides difficile to proliferate unchecked. This pathogen outcompetes residual flora and secretes toxins that further damage the intestinal environment. Understanding microbiota modulation by antibiotics helps explain why antibiotic use can worsen dysbiosis and increase infection risk.

Diet significantly influences microbial composition and dysbiosis risk. Diets high in dietary fiber promote growth of Bacteroidota, which produce short-chain fatty acids like butyrate that support colonic health and regulate immune responses. Conversely, high-fat diets favor Bacillota, linked to enhanced energy harvest and adiposity, potentially contributing to dysbiosis and metabolic dysfunction.

Dysbiosis reduces production of microbiota-derived protective metabolites and increases pro-inflammatory signaling, which degrades tight junction proteins between epithelial cells. This increased intestinal permeability, or leaky gut, allows bacterial components like lipopolysaccharides to enter the bloodstream, triggering systemic inflammation and contributing to cardiometabolic disease risk.

Circulating lipopolysaccharides act as endotoxins, activating immune cells and adipocytes to secrete pro-inflammatory cytokines. This promotes lipid accumulation in arterial walls and systemic low-grade inflammation. These effects have been associated with increased cardiometabolic risk, including obesity, atherosclerosis, and metabolic syndrome, based on experimental models and observational human studies.

Persistent dysbiosis is linked to inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Altered microbial composition perpetuates mucosal inflammation and immune dysregulation, creating a cycle of intestinal damage. Understanding these relationships is critical for developing microbiome-targeted therapies to restore microbial balance and reduce chronic inflammation.

Healthy microbiota produce protective metabolites, particularly short-chain fatty acids, that support intestinal barrier integrity and regulate immune responses. Dysbiosis reduces this metabolite production, eliminating a key defense against pro-inflammatory signaling. Restoring beneficial bacteria that produce these metabolites is essential for reversing dysbiosis and preventing associated chronic inflammatory diseases.